News from Cantargia AB A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Cantargia AB

16 Apr, 2018, 14:06 BST Cantargia Presents Anti-metastatic Effect of IL1RAP Blocking Antibody at AACR

Today, Cantargia AB presents novel data using antibody therapy against interleukin 1 receptor accessory protein (IL1RAP) at the American...


15 Mar, 2018, 07:40 GMT Cantargia Presents New Data at AACR on Inhibition of Metastasis by Antibodies Against IL1RAP

Cantargia AB ("Cantargia") today announces that data on the anti-metastatic properties of an antibody against interleukin 1 receptor accessory...


06 Mar, 2018, 14:38 GMT Cantargia: Antibody Against ILRAP Reduce Metastases in Experimental Cancer Model

Cantargia AB ("Cantargia") today announces that antibody blockade of IL1RAP signalling, reduce metastases in an experimental cancer model. The...


27 Feb, 2018, 07:38 GMT Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Leukemia

Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US...


23 Jan, 2018, 13:18 GMT Cantargia's European Patent for Hematological Cancers Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of hematological...


22 Jan, 2018, 10:19 GMT European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Hematological Cancers

In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment...


19 Jan, 2018, 10:43 GMT Cantargia's European Patent for Solid Tumours Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of solid tumours...


09 Jan, 2018, 15:41 GMT European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Solid Tumours

In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment...


05 Jan, 2018, 07:51 GMT Cantargia Receives Patent Approval in China for Antibody Treatment Against IL1RAP in Solid Tumours

Cantargia AB ("Cantargia") announces that the Chinese patent office, the State Intellectual Property Office ("SIPO"), has formally approved the...


04 Jan, 2018, 09:22 GMT Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Solid Tumours

Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the...


10 Nov, 2017, 12:32 GMT Notice of Extraordinary General Meeting in Cantargia AB (publ)

The shareholders of Cantargia AB (publ) are summoned to an extraordinary general meeting on Monday 27 November 2017 at 15.00 CET at Medicon...


09 Nov, 2017, 18:58 GMT Cantargia: Combined Directed Issue and Fully Guaranteed Rights Issue of 232 MSEK for Its Expanded Clinical Program of Immuno-oncology Antibody CAN04

The Board of Directors of Cantargia AB (publ) ("Cantargia" or the "Company") resolved on November 9, 2017 to carry out a directed new share issue...


08 Nov, 2017, 08:50 GMT Cantargia Publishes Interim Report for Third Quarter of 2017

Cantargia AB's ("Cantargia") interim report for the third quarter of 2017 is now available on the company's web page...


13 Oct, 2017, 07:47 BST Cantargia Announces First Patient Treated and Completed a Three Weeks Safety Evaluation Period With Immuno-oncology Antibody CAN04

Cantargia AB ("Cantargia") today announces that the first patient in the CANFOUR clinical trial has received three cycles of treatment with the...


06 Oct, 2017, 10:16 BST Cantargia Obtains Patent Approval in USA for the Antibody CAN04 in Development for Treatment of Cancer

Cantargia AB ("Cantargia") today announces that the United States Patent and Trademark Office ("USPTO") has granted the company's patent...


31 Aug, 2017, 15:26 BST Cantargia Obtains Patent Approval in Europe for the Antibody CAN04 in Development for Treatment of Cancer

Cantargia AB ("Cantargia") today announced that the European Patent Office ("EPO") has granted the company's patent application on...


23 Aug, 2017, 08:23 BST Cantargia Publishes Half Year Report

Cantargia AB's ("Cantargia") half year for the period January until June 2017 is now available on the company's web page...


21 Jul, 2017, 07:52 BST Cantargia Gains Approval to Initiate the CANFOUR Clinical Trial of Immuno-oncology Product Candidate CAN04

Cantargia AB ("Cantargia") today announced that the clinical trial application to study the antibody CAN04 in patients with cancer has been...


26 Jun, 2017, 07:53 BST Cantargia: Preclinical Studies of IL1RAP and CAN04 in Solid Tumours Presented at EACR-AACR-SIC in Florence

Results generated with Cantargia AB's ("Cantargia") CAN04 product candidate were presented at the joint meeting of the European, American...


16 Jun, 2017, 07:56 BST Cantargia AB and Panorama Research Inc. Sign Agreement to Develop an Antibody for Treatment of Autoimmune and Inflammatory Diseases

STOCKHOLM, June 16, 2017 /PRNewswire/-- Cantargia AB ("Cantargia") of Lund, Sweden, and Panorama Research Inc. ("Panorama"), a California based...


15 May, 2017, 09:21 BST Cantargia Publishes Interim Report for January-March 2017

Cantargia AB's ('Cantargia') interim report for January-March 2017 is now available on the company's web page...


12 May, 2017, 13:50 BST Cantargia's Application to Investigate the Antibody Product Candidate CAN04 in the CANFOUR Phase I/IIa Clinical Trial has been Submitted

Cantargia AB ("Cantargia") today announced that the company has submitted the first application to start a phase I/IIa clinical trial with the...


08 May, 2017, 07:47 BST Cantargia's Product Candidate CAN04 Shows Good Safety Properties in Studies Performed Under GLP

Cantargia AB ("Cantargia") today announced that the company has finalised the GLP safety studies of the product candidate CAN04 prior to the start...


05 Apr, 2017, 13:27 BST Cantargia Receives an Intention to Grant Notice in Europe for its CAN04 Product Candidate

Cantargia AB ("Cantargia") today announced that the company has received an Intention to Grant notice from the European Patent Office ("EPO") for...


05 Jan, 2017, 07:40 GMT Cantargia's Research and Development to be Presented at Biotech Showcase in San Francisco on 9 January 2017

Cantargia AB's ("Cantargia") CEO, Göran Forsberg, will be giving a presentation of the company at the Biotech Showcase conference in San...